Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02009488 · ClinicalTrials.gov registry record · Phase 1
Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 59
- Enrollment target
NCT02009488 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 59 participants.
The verdict
NCT02009488, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 59 participants
- Enrollment target
Study Summary
The purpose of this study is to assess changes from baseline in insulin sensitivity, hepatic fat content and beta cell function after approximately 24-25 weeks of treatment with canagliflozin compared to placebo in participants with type 2 diabetes mellitus (T2DM) with inadequate glycemic (blood sugar) control on metformin monotherapy or on combination therapy with metformin and a dipeptidyl peptidase-4 (DPP-4) inhibitor.
Interventions
- DRUG Placebo
- DRUG Canagliflozin, 300 mg
- DRUG Canagliflozin, 100 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2014-09-08 |
| Est. Completion | 2017-01-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02009488
The ClinicalTrials.gov registry entry for NCT02009488 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02009488 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02009488 about?
NCT02009488 is a clinical study titled "Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)". The purpose of this study is to assess changes from baseline in insulin sensitivity, hepatic fat content and beta cell function after approximately 24-25 weeks of treatment with canagliflozin compared to placebo in participants with type 2 diabetes mellitus (T2DM) with inadequate glycemic (blood sug...
What is the current status of trial NCT02009488?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 59 participants. The study started on 2014-09-08. Estimated completion is 2017-01-03.
What interventions are being tested in trial NCT02009488?
The interventions under investigation include: Placebo (DRUG), Canagliflozin, 300 mg (DRUG), Canagliflozin, 100 mg (DRUG).
Who is sponsoring clinical trial NCT02009488?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.